UNITED LAB's Tadalafil Tablet Receives Market Approval in China

Stock News07-02

The pharmaceutical company UNITED LAB (03933) has announced that its Tadalafil tablets, produced by its wholly-owned subsidiary Zhuhai United Laboratories Zhongshan Branch, have received marketing approval from China's National Medical Products Administration.

The approved tablets come in three dosages: 5mg, 10mg, and 20mg, with corresponding approval numbers.

Tadalafil is a selective inhibitor of phosphodiesterase type 5 (PDE5), indicated for the treatment of erectile dysfunction and erectile dysfunction combined with benign prostatic hyperplasia.

A key advantage of this medication compared to similar drugs is its long duration of action, lasting up to 36 hours, and its efficacy is not affected by food intake, offering patients a more flexible treatment option and expanding its clinical application value.

This new approval further diversifies the company's product portfolio and is expected to enhance its market competitiveness and brand influence within the men's health sector.

Moving forward, the company remains committed to new product research and development, continuously striving to improve its competitiveness and innovative capacity within the pharmaceutical industry, with the aim of generating greater returns for the company and its shareholders.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1120918669?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-02 17:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120918669","market":"us","top_or_hot":-1,"title":"UNITED LAB's Tadalafil Tablet Receives Market Approval in China","media":"Stock News","content":"<p>The pharmaceutical company <b>UNITED LAB</b> (<b>03933</b>) has announced that its Tadalafil tablets, produced by its wholly-owned subsidiary Zhuhai United Laboratories Zhongshan Branch, have received marketing approval from China's National Medical Products Administration.<br><br>The approved tablets come in three dosages: 5mg, 10mg, and 20mg, with corresponding approval numbers.<br><br>Tadalafil is a selective inhibitor of phosphodiesterase type 5 (PDE5), indicated for the treatment of erectile dysfunction and erectile dysfunction combined with benign prostatic hyperplasia.<br><br>A key advantage of this medication compared to similar drugs is its long duration of action, lasting up to 36 hours, and its efficacy is not affected by food intake, offering patients a more flexible treatment option and expanding its clinical application value.<br><br>This new approval further diversifies the company's product portfolio and is expected to enhance its market competitiveness and brand influence within the men's health sector.<br><br>Moving forward, the company remains committed to new product research and development, continuously striving to improve its competitiveness and innovative capacity within the pharmaceutical industry, with the aim of generating greater returns for the company and its shareholders.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UNITED LAB's Tadalafil Tablet Receives Market Approval in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUNITED LAB's Tadalafil Tablet Receives Market Approval in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-02 17:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>The pharmaceutical company <b>UNITED LAB</b> (<b>03933</b>) has announced that its Tadalafil tablets, produced by its wholly-owned subsidiary Zhuhai United Laboratories Zhongshan Branch, have received marketing approval from China's National Medical Products Administration.<br><br>The approved tablets come in three dosages: 5mg, 10mg, and 20mg, with corresponding approval numbers.<br><br>Tadalafil is a selective inhibitor of phosphodiesterase type 5 (PDE5), indicated for the treatment of erectile dysfunction and erectile dysfunction combined with benign prostatic hyperplasia.<br><br>A key advantage of this medication compared to similar drugs is its long duration of action, lasting up to 36 hours, and its efficacy is not affected by food intake, offering patients a more flexible treatment option and expanding its clinical application value.<br><br>This new approval further diversifies the company's product portfolio and is expected to enhance its market competitiveness and brand influence within the men's health sector.<br><br>Moving forward, the company remains committed to new product research and development, continuously striving to improve its competitiveness and innovative capacity within the pharmaceutical industry, with the aim of generating greater returns for the company and its shareholders.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IPOS","symbol_name":"Renaissance International IPO ETF","start_time":0,"source_url":"","article_id":"1120918669","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120918669","pubTimestamp":1782985240,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"The pharmaceutical company UNITED LAB (03933) has announced that its Tadalafil tablets, produced by its wholly-owned subsidiary Zhuhai United Laboratories Zhongshan Branch, have received marketing...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IPOS":"Renaissance International IPO ETF","IE00B3M56506.USD":"NEUBERGER BERMAN EMERGING MARKETS EQUITY \"A\" (USD) ACC","BK1191":"制药","03933":"联邦制药"},"translate_title":"联邦制药他达拉非片在中国获批上市","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03933":1,"IPOS":1},"content_text":"The pharmaceutical company UNITED LAB (03933) has announced that its Tadalafil tablets, produced by its wholly-owned subsidiary Zhuhai United Laboratories Zhongshan Branch, have received marketing approval from China's National Medical Products Administration.The approved tablets come in three dosages: 5mg, 10mg, and 20mg, with corresponding approval numbers.Tadalafil is a selective inhibitor of phosphodiesterase type 5 (PDE5), indicated for the treatment of erectile dysfunction and erectile dysfunction combined with benign prostatic hyperplasia.A key advantage of this medication compared to similar drugs is its long duration of action, lasting up to 36 hours, and its efficacy is not affected by food intake, offering patients a more flexible treatment option and expanding its clinical application value.This new approval further diversifies the company's product portfolio and is expected to enhance its market competitiveness and brand influence within the men's health sector.Moving forward, the company remains committed to new product research and development, continuously striving to improve its competitiveness and innovative capacity within the pharmaceutical industry, with the aim of generating greater returns for the company and its shareholders.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1120918669","isCrawlerRequest":true}